TGA is Drawing a Hard Line Between Biosimilars, Generics
By Mari Serebrov
Tuesday, August 6, 2013
Despite their "conceptual parallels," biosimilars are in no way, shape or form to be confused with generics. That's the message the Australian Therapeutics Goods Administration (TGA) sent out repeatedly in its latest guidance on follow-on biologics as it made it clear there would be no automatic substitution down under for biosimilars.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.